LAG3 and cancer: Also, it is notable that a new phase I/II clinical trial (NCT03459222) has recently been opened to investigate the efficacy of triple targeting LAG-3, PD-1, and CTLA-4, which may be a novel combinatorial strategy in cancer treatment and autoimmune disorders.